Taking the cholesterol drug torcetrapib was more effective than a placebo in lowering blood glucose levels in patients with type 2 diabetes, an Australian study in Circulation found. Torcetrapib-treated patients had an average hemoglobin A1c of 7.06% at the end of the study, compared with 7.29% in those who took a placebo, experts said. The drug, however, increases the risk of cardiovascular problems and death. "This won't change practice for now," endocrinologist Spyros Mezitis said. "We need more studies to understand the pathophysiology, and we need solid cardiovascular evidence for the other agents in this class."
Published in Brief: